Predictive and prognostic role of tumor-infiltrating lymphocytes for early breast cancer according to disease subtypes: Sensitivity analysis of randomized trials in adjuvant and neoadjuvant setting

Oncologist

Volumn 21, Issue 3, 2016, Pages 283-291

  Carbognin, Luisa ^a   Pilotto, Sara ^a   Nortilli, Rolando ^a   Brunelli, Matteo ^a   Nottegar, Alessia ^a   Sperduti, Isabella ^b   Giannarelli, Diana ^b   Bria, Emilio ^a   Tortora, Giampaolo ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant; Breast cancer; Neoadjuvant; Prognosis; Sensitivity analysis; Tumor infiltrating lymphocytes

Indexed keywords

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; HUMAN; IMMUNE RESPONSE; INFORMATION PROCESSING; MEDLINE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; FEMALE; IMMUNOLOGY; NEOADJUVANT THERAPY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960503302     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0307     Document Type: Article

References (52)

1. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734–1736.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252–264.
3. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903–907.
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011;331:1565–1570.
5. Melero I, Gaudernack G, Gerritsen W et al. Therapeutic vaccines for cancer: An overview of clinical trials. Nat Rev Clin Oncol 2014;11:509–524.
6. Fousek K, Ahmed N. The evolution of T-cell therapies for solid malignancies. Clin Cancer Res 2015;21:3384–3392.
7. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11–22.
8. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl JMed 2010;363:711–723.
9. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257–265.
10. Robert C, Ribas A, Wolchok JD et al. Antiprogrammed- death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109–1117.
11. Salgado R, Denkert C, Demaria S et al; International TILsWorking Group 2014.The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015;26:259–271.
12. Aaltomaa S, Lipponen P, Eskelinen M et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28A: 859–864.
13. Ménard S, Tomasic G, Casalini P et al. Lymphoid infiltration as a prognostic variable for early-onset breastcarcinomas. Clin Cancer Res1997;3:817–819.
14. Mohammed ZM, Going JJ, Edwards J et al. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 2012;107:864–873.
15. Mahmoud SM, Paish EC, Powe DG et al. Tumorinfiltrating CD81 lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949–1955.
16. Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triplenegative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014;32:2959–2966.
17. Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol 2014;25:1544–1550.
18. Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breastcancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicinwith doxorubicinbased chemotherapy: BIG 02-98. J ClinOncol 2013;31: 860–867.
19. Ibrahim EM, Al-Foheidi ME, Al-Mansour MM et al. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: A meta-analysis. Breast Cancer Res Treat 2014;148: 467–476.
20. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014;384:164–172.
21. Denkert C, Loibl S, Noske A et al. Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105–113.
22. Issa-Nummer Y, Darb-Esfahani S, Loibl S et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer–a substudy of the neoadjuvant Gepar Quinto trial. PLoS One 2013;8:e79775.
23. Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin inhumanepidermal growth factor receptor 2- positive and triple-negative primary breast cancers. J Clin Oncol 2015;33:983–991.
24. Mao Y, Qu Q, Zhang Y et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer:Asystematic reviewand meta-analysis. PLoS One 2014;9:e115103.
25. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet Oncol 2001;2: 475–482.
26. Bria E, Gralla RJ, Raftopoulos H et al. Magnitude of benefit of adjuvant chemotherapy for nonsmall cell lung cancer: meta-analysis of randomized clinical trials. Lung Cancer 2009;63:50–57.
27. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Intervention, 4.2.6. The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2006.
28. Altman DG, Bland JM. Interaction revisited: The difference between two estimates. BMJ 2003; 326:219.
29. Pilotto S, Di Maio M, Peretti U et al. Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials. Crit Rev Oncol Hematol 2014;90: 135–145.
30. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–2834.
31. Tierney JF, Stewart LA, Ghersi D et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
32. Bria E, Milella M, Cuppone F et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: A meta-analysis. Ann Oncol 2011;22: 2277–2285.
33. Dieci MV, Bisagni G, Cagossi K et al. Abstract PD1-1: Tumor infiltrating lymphocytes and correlation withoutcomein the Cher-LOB study. Cancer Res 2015;75: PD1–PD1.
34. Dieci MV, Mathieu MC, Guarneri V et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. AnnOncol 2015;26:1698–1704.
35. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl JMed 2010;363:1938–1948.
36. Criscitiello C, Azim HA Jr., Schouten PC et al. Understanding the biology of triple-negative breast cancer. Ann Oncol 2012;23(suppl 6): vi13–vi18.
37. Abramson VG, Lehmann BD, Ballinger TJ et al. Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 2015;121:8–16.
38. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750–2767.
39. Popova T, Manié E, Rieunier G et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012;72:5454–5462.
40. Matsumoto H, Koo SL, Dent R et al. Role of inflammatory infiltrates in triple negative breast cancer. J Clin Pathol 2015;68:506–510.
41. Ménard C, Martin F, Apetoh L et al. Cancer chemotherapy: not only adirect cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57:1579–1587.
42. Ladoire S, Arnould L, Apetoh L et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp31 regulatory T cells. Clin Cancer Res 2008;14:2413–2420.
43. Carson WE 3rd, Shapiro CL, Crespin TR et al. Cellular immunity in breast cancer patients completing taxane treatment. Clin Cancer Res 2004;10: 3401–3409.
44. Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361–370.
45. Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS One 2014;9:e88557.
46. Carbognin L, Pilotto S, Milella M et al. differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015;10: e0130142.
47. Nanda R, Chow LQ, Dees EC et al. Abstract S1- 09:Aphase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015;75:S1–S09.
48. Emens LA, Braiteh FS, Cassier P et al. Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triplenegative breast cancer. Cancer Res 2015;75:PD1-6.
49. ClinicalTrials.gov. http://www.clinicaltrials.gov.
50. Perez EA, Ballman KV, Anderson SK et al. Abstract S1-06: Stromal tumor-infiltrating lymphocytes(S-TILs): In the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit. Cancer Res 2015;75: S1–S06.
51. Bianchini G, Gianni L.The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014;15:e58–e68.
52. Salgado R, Denkert C, Campbell C et al. Tumorinfiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO Trial. JAMA Oncol 2015;1:448–454.